Abstract
The growth inhibitory effects of human fibroblast interferon (IFN-β) and controlled-releas needle of antitumor drugs, Mitomycin (MMC) or Adriamycin (ADM) on human hepatocellular carcinoma (HCC) cell line PLC/PRF/5 by intratumoral injection were examined. Nude mice with xenografted tumors derived from the PLC/PRF/5 cell line were treated with IFN-β twice a week for 5 weeks. Neither an IFN dose of 6×104IU/day nor 3×105IU/day was able to reduce the tumor weight and the AFP production. On the other hand, the combination of controlled-release needles plus IFN-β at a dose of 3×105IU was more effective than these needles alone. These results suggest that intratumoral injection of IFN-β may be of benefit to the patients with HCC when administered in combination with antitumor chemotherapy.
